Clinical Trials List
2010-08-01 - 2012-12-31
Phase III
Terminated5
ICD-10D05.00
Lobular carcinoma in situ of unspecified breast
ICD-10D05.01
Lobular carcinoma in situ of right breast
ICD-10D05.02
Lobular carcinoma in situ of left breast
ICD-10D05.10
Intraductal carcinoma in situ of unspecified breast
ICD-10D05.11
Intraductal carcinoma in situ of right breast
ICD-10D05.12
Intraductal carcinoma in situ of left breast
ICD-10D05.80
Other specified type of carcinoma in situ of unspecified breast
ICD-10D05.81
Other specified type of carcinoma in situ of right breast
ICD-10D05.82
Other specified type of carcinoma in situ of left breast
ICD-10D05.90
Unspecified type of carcinoma in situ of unspecified breast
ICD-10D05.91
Unspecified type of carcinoma in situ of right breast
ICD-10D05.92
Unspecified type of carcinoma in situ of left breast
ICD-9233.0
Carcinoma in situ of breast
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Fang-Ming Chen Division of Hematology & Oncology
- Fu Ouyang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林璟宏 Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
- 郭文宏 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 邱仁輝 Division of General Surgery
- 金光亮 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chih-Jung Chen Division of General Surgery
- Liang-Chih Liu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
216 participants
